Advances in treating insomnia

Cleveland Clinic Journal of Medicine

Volumn 74, Issue 4, 2007, Pages 251-266

  Budur, Kumar ^a   Rodriguez, Carlos ^a   Foldvary Schaefer, Nancy ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34247096130     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.74.4.251     Document Type: Review

References (75)

1. Leger D, Scheuemaier K, Philip P, Paillard M, Guilleminault C. SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosom Med 2001; 63:49-55.
2. Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II. Sleep 1999; 22(suppl 2):S354-S358.
3. Walsh JK, Engelhardt CL. The direct costs of insomnia in the United States for 1995. Sleep 1999; 22(suppl 2):S386-S393.
4. Leger D, Levy E, Paillard M. The direct costs of insomnia in France. Sleep 1999; 22(suppl 2):S394-S401.
5. Schweitzer PK, Engelhardt CL, Hilliker NA, Muehlbach MJ, Walsh JK. Consequences of reported poor sleep [abstract]. Sleep Res 1992; 21:260.
6. Gallup Organization. Sleep in America. Princeton, NJ: The Gallup Organization, 1991.
7. Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med 1998; 158:1099-1107.
8. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996; 39:411-418.
9. American Academy of Sleep Medicine. International Classification of Sleep Disorders, 2nd ed. Diagnostic and Coding Manual.
10. Satela MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia. An American Academy of Sleep Medicine review. Sleep 2000; 23:243-308.
11. Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004; 65(suppl 8):13-19.
12. Johnson EO, Roehrs T, Roth T, Breslau N. Epidemiology of alcohol and medication as aids to sleep in early adulthood. Sleep 1998; 21:178-186.
13. National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic insomnia in Adults, June 13-15, 2005. Sleep 2005; 28:1049-1057.
14. Morin CM, Stone J, Trinkle D, Mercer J, Remsberg S. Dysfunctional beliefs and attitudes about sleep among older adults with and without insomnia complaints. Psychol Aging 1993; 8:463-467.
15. Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE. Does cognitive-behavioral insomnia therapy alter dysfunctional beliefs about sleep? Sleep 2001; 24:591-599.
16. Billiard M, Bentley A. Is insomnia best categorized as a symptom or a disease? Sleep Med 2004; 5(suppl 1):S35-540.
17. Buysse DJ, Reynolds CF 3rd, Kupfer DJ, et al. Clinical diagnoses in 216 insomnia patients using the International Classification of Sleep Disorders (ICSD), DSM-IV and ICD-10 categories: a report from the APA/ NIMH DSM-IV Field Trial. Sleep 1994; 17:630-637.
18. Buysse DJ. Opening up new avenues for insomnia treatment research. Sleep 2003; 26:786-787.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Diagnostic criteria for primary insomnia, 1999.
20. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 1985; 42:225-232.
21. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997; 154:1417-1423.
22. Phillips B, Mannino DM. Does insomnia kill? Sleep 2005; 28:965-971.
23. National Sleep Foundation. Sleep in America poll 2005; 28-29.
24. Klink ME, Quan SF, Kaltenborn WT, Lebowitz MD. Risk factors associated with complaints of insomnia in a general population. Influence of previous complaints of insomnia. Arch Intern Med 1992; 152:1634-1637.
25. Ancoli-Israel S, Cooke JR. Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. J Am Geriatr Soc 2005; 53(suppl 7):S264-S271.
26. Morin CM, Blais J, Savard J. Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia? Behav Res Ther 2002; 40:741-752.
27. Espie CA, Inglis SJ, Tessler S, Harvey L. The clinical effectiveness of cognitive behaviour therapy for chronic insomnia: implementation and evaluation of a sleep clinic in general medical practice. Behav Res Ther 2001; 39:45-60.
28. Morin CM. Cognitive-behavioral approaches to the treatment of insomnia. J Clin Psychiatry 2004; 65(suppl 16):S33-S40.
29. Satela MJ, Pigeon WR. Identification and management of insomnia. Med Clin North Am 2004; 88:567-596.
30. Mendelson WB, Roth T, Cassella J, et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med Rev 2004; 8:7-17.
31. Krystal AD. The changing perspective on chronic insomnia management. J Clin Psychiatry 2004; 65(suppl 8):S20-S25.
32. Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003; 17:825-837.
33. Steens RD, Pouliot Z, Miller TW, Kryger MH, George CF. Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep 1993; 16:318-326.
34. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med 2004; 164:1567-1572.
35. Lavoisy J, Zivkovic B, Benavides J, Perrault GH, Robert P. Contribution of zolpidem in the management of sleep disorders. Encephale 1992; 18:379-392.
36. Scharf MB, Roth T, Vogel GW, Walsh JR. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994; 55:192-199.
37. Kryger MH, Steljes D, Pouliot Z, Neufeld H, Odynski T. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem. Sleep 1991; 14:399-407.
38. Nicholson AN, Pascoe PA. Hypnotic activity of an imidazo-pyridine (zolpidem). Br J Clin Pharmacol 1986; 21:205-211.
39. Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL. The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res 1992; 20:162-170.
40. Barbera J, Shapiro C. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf 2005; 28:301-318.
41. Walsh JK, Vogel GW, Scharf M, et al. A five-week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 2000; 1:41-49.
42. Rush CR, Frey JM, Griffiths RR. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl) 1999; 145:39-51.
43. Troy SM, Lucki I, Unruh MA, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol 2000; 20:328-337.
44. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6 weeks of treatment for primary insomnia. Curr Med Res Opin 2004; 20:1979-1991.
45. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo controlled study in adults with chronic insomnia. Sleep 2003; 26:793-799.
46. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005; 6.487-495.
47. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48:301-310.
48. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/ MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005; 28:303-307.
49. Zammit G, Roth T, Erman M, Salnati S, Weigand S, Zhang J. Polysomnography and outpatient study to determine the efficacy of ramelteon in adults with chronic insomnia [abst]. American Psychiatric Association 2005 Annual Meeting; May 21-26, 2005; Atlanta, GA. Abstract NR613.
50. Roth T, Selden D, Salnati S, et al. Phase III outpatient trial of ramelteon for the treatment of chronic insomnia in elderly patients. Poster presented at the annual meeting of the American Geriatric Society, Orlando, FL, 2005.
51. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998; 32:680-691.
52. Brzezinski A. Melatonin in humans. N Engl J Med 1997; 336:186-195.
53. Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 2003; 17:273-285.
54. Hughes RJ, Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep 1997; 20:124-131.
55. Dawson D, Encel N. Melatonin and sleep in humans. J Pineal Res 1993; 15:1-12.
56. Gilbert SS, van den Heuvel CJ, Dawson D. Daytime melatonin and temazepam in young adult humans: equivalent effects on sleep latency and body temperatures. J Physiol 1999; 514:905-914.
57. Ellis CM, Lemmens G, Parkes JD. Melatonin and insomnia. J Sleep Res 1996; 5:61-65.
58. James SP, Sack DA, Rosenthal NE, Mendelson WB. Melatonin administration in insomnia. Neuropsychopharmacology 1990; 3:19-23.
59. Waldhauser F, Waldhauser M, Lieberman HR, Deng MH, Lynch HJ, Wurtman RJ. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984; 39:307-313.
60. Guardiola-Lemaitre B. Toxicology of melatonin. J Biol Rhythms 1997; 12:697-706.
61. Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ, Deng MH. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA 1994; 91:1824-1828.
62. Zhdanova IV, Lynch HJ, Wurtman RJ. Melatonin: a sleep-promoting hormone. Sleep 1997; 20:899-907.
63. Voordouw BC, Euser R, Verdonk RE, et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab 1992; 74:108-117.
64. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002; 22:511-515.
65. Johnson EO, Roehrs T, Roth T, Breslau N. Epidemiology of alcohol and medication as aids to sleep in early adulthood. Sleep 1998; 21:178-186.
66. Roth T, Roehrs T, Zorick F, Conway W. Pharmacological effects of sedative-hypnotics, narcotic analgesics, and alcohol during sleep. Med Clin North Am 1985; 69:1281-1288.
67. Bon OL. Low-dose trazodone effective in insomnia. Pharmacopsychiatry 2005; 38:226.
68. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005; 66:469-476.
69. Wheatley D. Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. J Psychopharmacol 2005; 19:414-421.
70. Gruenwald J, Feder J. Kava, the present European situation. Nutraceuticals World 2002: January 2.
71. US Food and Drug Administration. Consumer advisory. March 25, 2002. Kava-containing dietary supplements may be associated with severe liver injury. www.cfsan.fda.gov/~dms/addskava.html.
72. Food Standards Agency, UK. www.food.gov.uk.
73. Bressler R. Herb-drug interactions: interactions between kava and prescription medications. Geriatrics 2005; 60:24-25.
74. Singh YN. Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 2005; 100:108-113.
75. Mennini T, Bernasconi P, Bombardelli E, et al. In-vitro study on the interaction of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbiturate receptors in the rat brain. Fitoterapia 1993; 64:291-300.